InvestorsHub Logo
Post# of 252218
Next 10
Followers 833
Posts 119848
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 198251

Monday, 12/14/2015 8:02:56 PM

Monday, December 14, 2015 8:02:56 PM

Post# of 252218
RBC cut its price target on ESPR from $65 to $40—presumably based on the negative FDA panel vote on Vytorin (#msg-119157187):


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.